Epigenetic targeting of histone deacetylases in diagnostics and treatment of depression

Hyun Sun Park; Jongmin Kim; Seong Hoon Ahn; Hong Yeoul Ryu

doi:10.3390/ijms22105398

Epigenetic targeting of histone deacetylases in diagnostics and treatment of depression

Hyun Sun Park, Jongmin Kim, Seong Hoon Ahn, Hong Yeoul Ryu

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

Depression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, accessible, and tolerable therapies. Pharmacological regulation of histone acetylation level has been investigated as one potential clinical strategy. Histone acetylation status is considered a potential diagnostic biomarker for depression, while inhibitors of histone deacetylases (HDACs) have garnered interest as novel therapeutics. This review describes recent advances in our knowledge of histone acetylation status in depression and the therapeutic potential of HDAC in-hibitors.

Original language	English
Article number	5398
Journal	International Journal of Molecular Sciences
Volume	22
Issue number	10
DOIs	https://doi.org/10.3390/ijms22105398
State	Published - 2 May 2021

Keywords

Anti-depressant therapy
Biomarker
Depression
Histone deacetylase (HDAC)

Access to Document

10.3390/ijms22105398

Cite this

@article{c0e1df09b7af4a1aaab9331f03bad218,

title = "Epigenetic targeting of histone deacetylases in diagnostics and treatment of depression",

abstract = "Depression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, accessible, and tolerable therapies. Pharmacological regulation of histone acetylation level has been investigated as one potential clinical strategy. Histone acetylation status is considered a potential diagnostic biomarker for depression, while inhibitors of histone deacetylases (HDACs) have garnered interest as novel therapeutics. This review describes recent advances in our knowledge of histone acetylation status in depression and the therapeutic potential of HDAC in-hibitors.",

keywords = "Anti-depressant therapy, Biomarker, Depression, Histone deacetylase (HDAC)",

author = "Park, \{Hyun Sun\} and Jongmin Kim and Ahn, \{Seong Hoon\} and Ryu, \{Hong Yeoul\}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = may,

day = "2",

doi = "10.3390/ijms22105398",

language = "English",

volume = "22",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Epigenetic targeting of histone deacetylases in diagnostics and treatment of depression

AU - Park, Hyun Sun

AU - Kim, Jongmin

AU - Ahn, Seong Hoon

AU - Ryu, Hong Yeoul

PY - 2021/5/2

Y1 - 2021/5/2

N2 - Depression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, accessible, and tolerable therapies. Pharmacological regulation of histone acetylation level has been investigated as one potential clinical strategy. Histone acetylation status is considered a potential diagnostic biomarker for depression, while inhibitors of histone deacetylases (HDACs) have garnered interest as novel therapeutics. This review describes recent advances in our knowledge of histone acetylation status in depression and the therapeutic potential of HDAC in-hibitors.

AB - Depression is a highly prevalent, disabling, and often chronic illness that places substantial burdens on patients, families, healthcare systems, and the economy. A substantial minority of patients are unresponsive to current therapies, so there is an urgent need to develop more broadly effective, accessible, and tolerable therapies. Pharmacological regulation of histone acetylation level has been investigated as one potential clinical strategy. Histone acetylation status is considered a potential diagnostic biomarker for depression, while inhibitors of histone deacetylases (HDACs) have garnered interest as novel therapeutics. This review describes recent advances in our knowledge of histone acetylation status in depression and the therapeutic potential of HDAC in-hibitors.

KW - Anti-depressant therapy

KW - Biomarker

KW - Depression

KW - Histone deacetylase (HDAC)

UR - http://www.scopus.com/inward/record.url?scp=85106182188&partnerID=8YFLogxK

U2 - 10.3390/ijms22105398

DO - 10.3390/ijms22105398

M3 - Review article

C2 - 34065586

AN - SCOPUS:85106182188

SN - 1661-6596

VL - 22

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 10

M1 - 5398

ER -

Epigenetic targeting of histone deacetylases in diagnostics and treatment of depression

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this